UBS Reinstates Buy on Charles River, Announces $357 Price Target

UBS analyst Kevin Caliendo has reinstated a Buy rating on Charles River Laboratories (NYSE: CRL) and set a price target of $357 for the stock. This recommendation indicates a positive outlook for the company's performance in the market.